Year All202420232022202120202019 Apr 26, 2022 Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia Apr 04, 2022 Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease Mar 24, 2022 Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference Mar 14, 2022 Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results Feb 23, 2022 Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference Jan 10, 2022 Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs Jan 03, 2022 Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference Nov 29, 2021 Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer Nov 10, 2021 Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results Nov 09, 2021 Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
Apr 26, 2022 Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
Apr 04, 2022 Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
Mar 24, 2022 Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
Mar 14, 2022 Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
Jan 10, 2022 Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
Nov 29, 2021 Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
Nov 10, 2021 Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
Nov 09, 2021 Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
